We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+40.5%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$47M
AUM Growth
-$538M
(-92%)
Cap. Flow
-$549M
Cap. Flow
% of AUM
-1,168.39%
Top 10 Holdings %
Top 10 Hldgs %
25.17%
Holding
313
New
6
Increased
35
Reduced
92
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Franklin FTSE India ETF
FLIN
|
+$334K |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$332K |
| 3 |
Enanta Pharmaceuticals
ENTA
|
+$224K |
| 4 |
Puma Biotechnology
PBYI
|
+$217K |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
+$217K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MPLX
MPLX
|
+$60.3M |
| 2 |
EQM
EQM Midstream Partners, LP
EQM
|
+$58.3M |
| 3 |
Energy Transfer Partners
ET
|
+$49.7M |
| 4 |
Enterprise Products Partners
EPD
|
+$41.7M |
| 5 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$30.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.12% |
| 2 | Financials | 0.73% |
| 3 | Communication Services | 0.52% |
| 4 | Consumer Discretionary | 0.46% |
| 5 | Materials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACHN
76
DELISTED
Achillion Pharmaceuticals
ACHN
| $257K | 0.55% |
86,904
-8,913
| -9% | -$21.9K |
|
77
BioCryst Pharmaceuticals
BCRX
$2.37B
| $255K | 0.54% |
31,277
-4,023
| -11% | -$34.4K |
|
|
MYOK
78
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $253K | 0.54% |
4,859
-735
| -13% | -$33.9K |
|
|
DCPH
79
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $246K | 0.52% |
10,578
-1,195
| -10% | -$31.3K |
|
|
AKCA
80
DELISTED
Akcea Therapeutics Inc
AKCA
| $242K | 0.51% |
8,527
-1,083
| -11% | -$31.5K |
|
|
TECX
81
Tectonic Therapeutic
TECX
$573M
| $239K | 0.51% |
904
-119
| -12% | -$21.8K |
|
|
ITCI
82
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $230K | 0.49% |
18,878
-2,735
| -13% | -$34.9K |
|
83
Xencor
XNCR
$1.44B
| $222K | 0.47% |
7,160
-1,069
| -13% | -$35.6K |
|
|
ESPR
84
DELISTED
Esperion Therapeutics
ESPR
| $220K | 0.47% |
5,483
-796
| -13% | -$35.7K |
|
|
ADAP
85
DELISTED
Adaptimmune Therapeutics
ADAP
| $218K | 0.46% |
50,655
-7,568
| -13% | -$35.2K |
|
86
Kiniksa Pharmaceuticals
KNSA
$4.83B
| $212K | 0.45% |
11,763
-1,773
| -13% | -$34.2K |
|
87
Wave Life Sciences
WVE
$1.12B
| $209K | 0.44% |
5,373
-613
| -10% | -$24.9K |
|
88
ProQR Therapeutics
PRQR
$243M
| $207K | 0.44% |
14,925
-1,757
| -11% | -$26.2K |
|
89
Neuronetics
STIM
$120M
| $206K | 0.44% |
13,535
-1,737
| -11% | -$28.7K |
|
90
Inovio Pharmaceuticals
INO
$79.8M
| $197K | 0.42% |
4,412
-621
| -12% | -$31.3K |
|
91
CytomX Therapeutics
CTMX
$705M
| $194K | 0.41% |
18,085
-2,330
| -11% | -$34.4K |
|
92
Crinetics Pharmaceuticals
CRNX
$8.86B
| $181K | 0.39% |
7,934
-1,100
| -12% | -$27K |
|
|
ALLK
93
DELISTED
Allakos
ALLK
| $180K | 0.38% |
4,437
-577
| -12% | -$23.3K |
|
94
Karyopharm Therapeutics
KPTI
$168M
| $160K | 0.34% |
1,826
-222
| -11% | -$24.6K |
|
|
GTHX
95
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $144K | 0.31% |
8,654
-1,300
| -13% | -$24.7K |
|
|
AMRS
96
DELISTED
Amyris Inc.
AMRS
| $137K | 0.29% |
65,658
-9,636
| -13% | -$38K |
|
|
IMGN
97
DELISTED
Immunogen Inc
IMGN
| $136K | 0.29% |
50,045
-6,826
| -12% | -$29.6K |
|
|
UBX
98
DELISTED
Unity Biotechnology
UBX
| $134K | 0.29% |
1,653
-246
| -13% | -$27.9K |
|
99
Alibaba
BABA
$269B
| $94K | 0.2% |
516
-68
| -12% | -$11.4K |
|
100
HDFC Bank
HDB
$119B
| $92K | 0.2% |
3,192
+640
| +25% | +$16.6K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q1 2019 Portfolio in Review
As of Q1 2019, Virtus ETF Advisers held 313 positions worth $47M, down 92% from $585M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Virtus ETF Advisers withdrew a net $549M in Q1 2019, closing 155 positions and reducing 92 holdings. Its most notable exit was MPLX, an estimated $60.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 7.3% a quarter earlier, followed by Financials and Communication Services.
Against the trend, Virtus ETF Advisers opened a new position in Meta Platforms (Facebook) worth $73K.
- Virtus ETF Advisers's largest Q1 2019 buy was Meta Platforms (Facebook): 435 shares worth $73K.
- Virtus ETF Advisers added most to Franklin FTSE India ETF in Q1 2019, an estimated $334K increase.
- Virtus ETF Advisers's biggest Q1 2019 reduction was Marathon Petroleum, cutting an estimated $21.6M.
- Virtus ETF Advisers fully exited MPLX in Q1 2019, selling an estimated $60.3M.
- Virtus ETF Advisers's ten largest holdings make up 25% of its $47M portfolio in Q1 2019.
- Virtus ETF Advisers opened 6 new positions and closed 155 in Q1 2019.
- Virtus ETF Advisers's portfolio value fell 92% quarter-over-quarter to $47M.
Based on Virtus ETF Advisers's 13F filing for Q1 2019, filed 14 May 2019.